Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Rating of “Moderate Buy” by Analysts

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have received a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $5.17.

Several brokerages have issued reports on SGMO. Barclays increased their price objective on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. Jefferies Financial Group lowered their price objective on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, December 31st. Wells Fargo & Company reduced their target price on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 31st. StockNews.com cut Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 24th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Sangamo Therapeutics in a research note on Monday, January 27th.

Hedge Funds Weigh In On Sangamo Therapeutics

Large investors have recently added to or reduced their stakes in the company. E Fund Management Co. Ltd. bought a new position in Sangamo Therapeutics during the fourth quarter worth $25,000. JPMorgan Chase & Co. lifted its stake in Sangamo Therapeutics by 679.5% during the fourth quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 21,793 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in Sangamo Therapeutics by 2,319.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 25,000 shares during the last quarter. SBI Securities Co. Ltd. bought a new position in Sangamo Therapeutics during the fourth quarter worth $28,000. Finally, Shelton Wealth Management LLC bought a new position in Sangamo Therapeutics during the fourth quarter worth $29,000. 56.93% of the stock is currently owned by institutional investors.

Sangamo Therapeutics Stock Down 4.4 %

Shares of NASDAQ:SGMO opened at $0.96 on Wednesday. Sangamo Therapeutics has a 52-week low of $0.30 and a 52-week high of $3.18. The company has a 50 day moving average of $1.38 and a two-hundred day moving average of $1.40. The company has a market capitalization of $199.49 million, a price-to-earnings ratio of -1.27 and a beta of 1.30.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.